Physician profile
Ryan Hood
NPI 1306501051
$10,526.54
in general payments reported to CMS, 2019-2025
28 companies · $6,156 in 2025
The $6,156 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $60.24 · 2023: $1,445 · 2024: $2,866 · 2025: $6,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,572 · Travel and Lodging: $2,004 · Consulting Fee: $1,750 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,571.80 |
| Travel and Lodging | $2,003.51 |
| Consulting Fee | $1,750.00 |
| Education | $140.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $4,322.58 | 2023-2025 | Zoryve |
| Abbvie INC. | $1,051.52 | 2022-2025 | |
| Janssen Biotech, INC. | $993.84 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $964.36 | 2023-2025 | |
| Dermavant Sciences, INC. | $481.13 | 2023-2024 | Vtama |
| Ucb, INC. | $336.91 | 2025 | Bimzelx |
| Incyte Corporation | $305.91 | 2023-2025 | Opzelura |
| Organon LLC | $213.29 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $202.03 | 2024-2025 | Nemluvio, Aklief |
| Verrica Pharmaceuticals INC. | $195.38 | 2023-2024 | Ycanth |
| Lilly USA, LLC | $189.23 | 2024-2025 | Ebglyss, Taltz |
| Pfizer INC. | $176.80 | 2024-2025 | |
| Leo Pharma INC. | $160.15 | 2022-2024 | Adbry |
| Mayne Pharma Commercial LLC | $153.35 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $130.14 | 2023-2024 | Sotyktu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $127.80 | 2023-2025 | Otezla, Enbrel, Otezla |
| Journey Medical Corporation | $115.95 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $105.59 | 2023-2025 | Winlevi |
| Regeneron Healthcare Solutions, INC. | $83.78 | 2024 | Dupixent, Libtayo |
| Botanix Sb INC | $33.55 | 2025 | Sofdra |
| Convatec INC. | $28.76 | 2023 | |
| Genzyme Corporation | $28.45 | 2023 | |
| Kyowa Kirin, INC. | $24.15 | 2025 | |
| Almirall LLC | $23.68 | 2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.71 | 2025 | Cabtreo, Siliq, Jublia |
| Lnhc, INC | $20.73 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.33 | 2024 | Spevigo |
| Paratek Pharmaceuticals, INC. | $15.44 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.